AU2023225518A1 - Chromanol compounds for treatment or prophylaxis of ageing-associated disorders - Google Patents

Chromanol compounds for treatment or prophylaxis of ageing-associated disorders Download PDF

Info

Publication number
AU2023225518A1
AU2023225518A1 AU2023225518A AU2023225518A AU2023225518A1 AU 2023225518 A1 AU2023225518 A1 AU 2023225518A1 AU 2023225518 A AU2023225518 A AU 2023225518A AU 2023225518 A AU2023225518 A AU 2023225518A AU 2023225518 A1 AU2023225518 A1 AU 2023225518A1
Authority
AU
Australia
Prior art keywords
compound
treatment
use according
ageing
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023225518A
Other languages
English (en)
Inventor
Robert Henk Henning
Guido Krenning
Daniël Henri SWART
Adrianus Cornelis Van Der Graaf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sulfateq BV
Original Assignee
Sulfateq BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sulfateq BV filed Critical Sulfateq BV
Publication of AU2023225518A1 publication Critical patent/AU2023225518A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2023225518A 2022-02-28 2023-02-28 Chromanol compounds for treatment or prophylaxis of ageing-associated disorders Pending AU2023225518A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2031091 2022-02-28
NL2031091A NL2031091B1 (en) 2022-02-28 2022-02-28 Chromanol compounds for treatment or prophylaxis of ageing and ageing-associated disorders
PCT/NL2023/050095 WO2023163596A1 (en) 2022-02-28 2023-02-28 Chromanol compounds for treatment or prophylaxis of ageing-associated disorders

Publications (1)

Publication Number Publication Date
AU2023225518A1 true AU2023225518A1 (en) 2024-09-12

Family

ID=83271289

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023225518A Pending AU2023225518A1 (en) 2022-02-28 2023-02-28 Chromanol compounds for treatment or prophylaxis of ageing-associated disorders

Country Status (10)

Country Link
US (1) US20250177384A1 (https=)
EP (1) EP4486317A1 (https=)
JP (1) JP2025506844A (https=)
CN (1) CN118742301A (https=)
AU (1) AU2023225518A1 (https=)
CA (1) CA3252944A1 (https=)
CL (1) CL2024002555A1 (https=)
NL (1) NL2031091B1 (https=)
WO (1) WO2023163596A1 (https=)
ZA (1) ZA202406418B (https=)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105806A1 (en) 2005-04-07 2006-10-12 Miso Sabovic Delaying the ageing process and disorders caused by ageing
EP2680838A1 (en) 2011-02-28 2014-01-08 Farmicom Pharmaceutical Company D.O.O. TREATMENT OF ARTERIAL AGEING BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR
KR102137450B1 (ko) 2012-07-12 2020-07-27 콘드리온 아이피 비.브이. 미토콘드리아 질환을 치료하기 위한 크로마닐 유도체
NL2010010C2 (en) 2012-12-19 2014-06-23 Sulfateq B V Compounds for protection of cells.
WO2015148522A1 (en) 2014-03-24 2015-10-01 Seals Douglas R Methods for treatment of vascular endothelial dysfunction using nicotinamide mononucleotide
NL2013012B1 (en) * 2014-06-17 2016-07-05 Sulfateq Bv Compounds for the treatment of chronic obstructive airway diseases.
US10815211B2 (en) 2015-10-08 2020-10-27 Khondrion Ip B.V. Compounds for treating mitochondrial disease
ES2959243T3 (es) * 2017-04-05 2024-02-22 Khondrion Ip B V Nuevo tratamiento de enfermedades mitocondriales
EP3672593B1 (en) * 2017-08-25 2024-12-18 Sulfateq B.V. Medicaments for the treatment of vasoconstriction related diseases or disorders
WO2019038360A1 (en) * 2017-08-25 2019-02-28 Sulfateq B.V. 6-CHROMANOL DERIVATIVES FOR USE AS A MEDICINAL PRODUCT
NL2024431B1 (en) * 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease
NL2026511B1 (en) * 2020-09-21 2022-05-24 Sulfateq Bv Compounds for treatment of heart failure

Also Published As

Publication number Publication date
US20250177384A1 (en) 2025-06-05
CN118742301A (zh) 2024-10-01
EP4486317A1 (en) 2025-01-08
NL2031091B1 (en) 2023-09-07
CL2024002555A1 (es) 2025-01-10
JP2025506844A (ja) 2025-03-13
WO2023163596A1 (en) 2023-08-31
ZA202406418B (en) 2025-11-26
CA3252944A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
ES2741439T3 (es) Compuestos aromáticos sustituidos
US6231894B1 (en) Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase
EP2111863A1 (en) Fasudil in combination with bosentan for the treament of pulmonary arterial hypertension
JP6882265B2 (ja) 心臓肥大および肺高血圧の治療用医薬の製造におけるカウラン化合物の使用
US20150272944A1 (en) Novel triglyceride reducing agent
JP7695246B2 (ja) アルツハイマー病の治療のための化合物
JP7749661B2 (ja) 心不全の処置のためのクロマノール化合物
WO2023152500A1 (en) Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine
US20250177384A1 (en) Chromanol compounds for treatment or prophylaxis of ageing-associated disorders
US20250025444A1 (en) Treatment of neurodegenerative diseases via administration of buntanetap and a phosphodiesterase inhibitor
US20100234366A1 (en) Use of Strobilurins for the Treatment of Disorders of Iron Metabolism
US20040087662A1 (en) Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
KR101360569B1 (ko) 우울증, 불안증, 정신분열증, 수면장애 및 간질의 치료를 위한 숙신산의 콜린염
HK40115454A (zh) 用於治疗或预防衰老相关病症的苯并二氢吡喃醇化合物
US20070049599A1 (en) Use of bh4 for the treatment of respiratory diseases
JP2023529612A (ja) 敗血症の治療のためのクロマノール、キノン又はヒドロキノン化合物
Chhajed et al. Lung transplantation: management and complications
US20160166577A1 (en) Treatment of pulmonary fibrosis using an inhibitor of cbp/catenin
JP7257091B2 (ja) 認知症の治療及び予防薬
WO2025221289A1 (en) Treatment of diseases via administration of buntanetap and a phosphodiesterase inhibitor
US20190262357A1 (en) Preventative or therapeutic agent for pulmonary hypertension including crude drug component
JP2019182845A (ja) キヌレニンアミノトランスフェラーゼ２（ｋａｔ２）阻害剤